Skip to main content
Skip to main content

AAP Gateway

Advanced Search »

User menu

  • Login
  • AAP Policy
  • Topic/Program Collections
  • Submit Manuscript
  • Alerts
  • Subscribe
  • aap.org

Menu

  • AAP Grand Rounds
  • AAP News
  • Hospital Pediatrics
  • NeoReviews
  • Pediatrics
  • Pediatrics in Review
  • Current AAP Policy
  • Journal CME
  • AAP Career Center
  • Pediatric Collections
  • AAP Journals Catalog

Sections

    • Login
    • AAP Policy
    • Topic/Program Collections
    • Submit Manuscript
    • Alerts
    • Subscribe
    • aap.org

    Get Involved! Pediatrics is accepting nominations for Editorial Board positions.

    Sign up for Insight Alerts highlighting editor-chosen studies with the greatest impact on clinical care.
    Video Abstracts -- brief videos summarizing key findings of new articles
    Watch the Features Video to learn more about Pediatrics.

    Advertising Disclaimer »

    Tools and Links

    Pediatrics
    January 2014, VOLUME 133 / ISSUE 1
    From the American Academy of Pediatrics
    Clinical Report

    Use of Inhaled Nitric Oxide in Preterm Infants

    Praveen Kumar, COMMITTEE ON FETUS AND NEWBORN
    • Article
    • Figures & Data
    • Info & Metrics
    • Comments
    Loading
    Download PDF

    Abstract

    Nitric oxide, an important signaling molecule with multiple regulatory effects throughout the body, is an important tool for the treatment of full-term and late-preterm infants with persistent pulmonary hypertension of the newborn and hypoxemic respiratory failure. Several randomized controlled trials have evaluated its role in the management of preterm infants ≤34 weeks’ gestational age with varying results. The purpose of this clinical report is to summarize the existing evidence for the use of inhaled nitric oxide in preterm infants and provide guidance regarding its use in this population.

    • inhaled nitric oxide
    • preterm infants
    • hypoxic respiratory failure
    • bronchopulmonary dysplasia
  • Abbreviations:
    BPD —
    bronchopulmonary dysplasia
    iNO —
    inhaled nitric oxide
    NO —
    nitric oxide
    NOCLD —
    Nitric Oxide Chronic Lung Disease study group
  • Introduction

    Nitric oxide (NO) is an important signaling molecule with multiple regulatory effects throughout the body. In perinatal medicine, inhaled nitric oxide (iNO) was initially studied for its pulmonary vasodilating effects in infants with pulmonary hypertension and has since become an important tool for the treatment of full-term and late-preterm infants with persistent pulmonary hypertension of the newborn and hypoxemic respiratory failure.1 Inhaled NO also has multiple and complex systemic and pulmonary effects. In animal models of neonatal chronic lung disease, iNO stimulates angiogenesis, augments alveolarization, improves surfactant function, and inhibits proliferation of smooth muscle cells and abnormal elastin deposition.2–6 Although the evidence for similar benefits in preterm infants is lacking, the off-label use of iNO in this population has escalated.7 A study published in 2010 reported a sixfold increase (from 0.3% to 1.8%) in the use of iNO among infants born at less than 34 weeks’ gestation between 2000 and 2008.7 The greatest increase occurred among infants who were born at 23 to 26 weeks’ gestation (0.8% to 6.6%). The National Institutes of Health convened a consensus panel in October 2010 to evaluate the evidence for safety and efficacy of iNO therapy in preterm infants. After reviewing the published evidence, the panel concluded that the available evidence does not support the use of iNO in early routine, early rescue, or later rescue regimens in the care of infants born at less than 34 weeks’ gestation and that hospitals, clinicians, and the pharmaceutical industry should avoid marketing iNO for this group of infants.8 An individual-patient data meta-analysis of 14 randomized controlled trials reached similar conclusions.9 The purpose of this clinical report is to summarize the existing evidence for the use of iNO in preterm infants and provide guidance regarding its use in this population.

    Literature Review

    Use of iNO in Preterm Infants With Respiratory Failure

    The benefits associated with iNO therapy in full-term and late-preterm infants with persistent pulmonary hypertension of the newborn and hypoxemic respiratory failure initiated interest in exploring whether iNO could reduce the rates of death and neonatal morbidities in more immature infants. Pilot studies reported short-term improvement in oxygenation with iNO, but no significant benefit was observed in mortality or other morbidities.10–15 Subsequently, several randomized clinical trials were undertaken.16–23 Table 1 outlines the study population, entry criteria, and dose and duration of iNO treatment and summarizes the outcomes for all published randomized controlled trials. Only 1 small trial of 40 patients reported a beneficial effect on survival (Table 1). Subgroup analyses of secondary outcomes have provided conflicting results. Post hoc analysis of the Neonatal Research Network study suggested that iNO therapy was associated with reduced rates of death and bronchopulmonary dysplasia (BPD) in infants with a birth weight greater than 1000 g, but higher mortality and increased risk of severe intracranial hemorrhage in infants weighing 1000 g or less at birth.17 In contrast, another large multicenter US trial reported no significant difference in the primary outcome of death or BPD between treated and control groups; however, infants treated with iNO had fewer brain lesions (eg, grade 3 or 4 intracranial hemorrhage, periventricular leukomalacia, and/or ventriculomegaly) noted on cranial ultrasonography.20 A European multicenter study reported that infants randomized to iNO treatment had longer duration of ventilation, time on oxygen therapy, and length of hospital stay compared with the placebo group, although none of these results were statistically significant.19

    View this table:
    • View inline
    • View popup
    TABLE 1

    Randomized Controlled Trials of iNO in Preterm Infants

    Use of iNO in Preterm Infants to Improve the Rate of Survival Without BPD

    Lung pathology in preterm infants with BPD is characterized by reduced numbers of large alveoli and abnormal pulmonary vasculature development. Surfactant deficiency, ventilator-induced lung injury, oxygen toxicity, and inflammation appear to play important roles in its pathogenesis.26,27 In animal models of neonatal lung injury, iNO promotes angiogenesis, decreases apoptosis, and reduces lung inflammation and oxidant injury.28–30 In an early study of iNO use in preterm infants, the incidence of BPD was reduced in treated infants who required ventilator support.16 Of 3 subsequent large randomized trials designed to evaluate the effect of iNO therapy on survival without BPD,20,24,25 2 found no significant benefit20,25 (Table 1). A third trial, which featured late treatment (7–21 days of age), a longer duration of drug exposure (25 days), and a higher cumulative dose, demonstrated a modest but statistically significant beneficial effect (44% iNO vs 37% placebo; P = .042).24 A subgroup analysis showed that the beneficial effect was seen in infants enrolled between 7 and 14 days of age but not those enrolled between the ages of 15 and 21 days.24

    Effects of iNO Therapy on Neurodevelopmental Outcome

    Studies in animal models suggest that iNO may have direct beneficial effects on the brain through mechanisms involving the cerebral vasculature and/or neuronal maturation.31,32 Other investigators have described a possible role for intravascular NO-derived molecules in conserving and stabilizing NO bioactivity that may contribute to the regulation of regional blood flow and oxygen delivery.33,34 Neurodevelopmental outcome has been reported for 6 clinical trials,35–40 and of these, 1 noted a more favorable neurodevelopmental outcome at 1 year of age among the preterm cohort treated with iNO but no difference in the rate of cerebral palsy.36

    Effects of iNO Therapy on Long-Term Pulmonary Outcome of Survivors

    In animal models, iNO decreases baseline airway resistance and may increase the rate of alveolarization.2–6 To date, only 2 studies have reported respiratory outcomes of preterm infants treated with iNO.41,42 In a telephone survey that included 456 infants in the Nitric Oxide Chronic Lung Disease (NOCLD) study group, the use of bronchodilators, inhaled steroids, systemic steroids, diuretics, and supplemental oxygen during the first year of life was less in the iNO-treated group, but there were no significant differences in the frequency of wheezing or the rate of rehospitalization. In the Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide multicenter trial, follow-up at 1 year of age showed no difference in maximal expiratory flow at functional residual capacity, wheezing, readmission rate, or use of respiratory medications.42

    Results of Meta-Analyses of Studies Evaluating the Use of iNO in Preterm Infants

    Two published meta-analyses found no overall significant effect of iNO on the rate of mortality, BPD, intraventricular hemorrhage, or neurodevelopmental impairment.43,44 In view of the limitations of meta-analysis using aggregate data from different trials and to identify any patient or treatment characteristics that might predict benefit, Askie et al9 conducted an individual-patient data meta-analysis. Data from 3298 infants in 11 trials that included 96% of published data showed no statistically significant effect of iNO on the rate of death or chronic lung disease (relative risk 0.96; 95% confidence interval 0.92–1.01) or severe brain lesions on cranial imaging (relative risk 1.12; 95% confidence interval 0.98–1.28). There were no statistically significant differences in iNO effect according to any of the patient-level characteristics tested; however, the authors cautioned that they could not exclude the possibility of a small reduction in the combined outcome of death or chronic lung disease if a higher dose of iNO (20 ppm) was used after >7 days of age, as observed in the NOCLD study.9,24

    Cost-Benefit Analyses of Routine Use of iNO in Preterm Infants

    Treatment with iNO is expensive and can add significantly to health care costs.8 A retrospective economic evaluation using patient-level data from the NOCLD trial (the only trial showing clinical benefit) reported that the overall mean cost per infant for the initial hospitalization was similar in the treated and placebo groups; however, when iNO therapy was initiated between 7 and 14 days of age, there was a 71% probability that the treatment decreased costs and improved outcomes.45 Cost-benefit analysis from 2 other studies failed to show any cost-benefit.37,39 Among preterm infants in the Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide trial, there was no difference in resource use and cost of care through the 4-year assessment.37 Using more robust research methodology, including data on postdischarge resource utilization and health-related quality of life evaluations, Watson et al39 found that costs of care did not vary significantly by treatment arm through 1 year of age. Although quality-adjusted survival was slightly better with iNO therapy, the estimated incremental cost-effectiveness ratio was $2.25 million per quality-adjusted life year, with only a 12.9% probability that the incremental cost-effectiveness ratio would be less than $500 000 per quality-adjusted life year. Additionally, in subgroup analysis, total costs were significantly higher for the iNO-treated group in the smallest birth weight stratum (500–749 g).

    Safety of iNO Use in Preterm Infants

    The only information regarding the safety of iNO use in preterm infants is derived from the NOCLD trial.46–49 The limited data suggest that iNO is safe and does not increase lung inflammation or oxidative stress.46,48

    Summary

    1. The results of randomized controlled trials, traditional meta-analyses, and an individualized patient data meta-analysis study indicate that neither rescue nor routine use of iNO improves survival in preterm infants with respiratory failure (Evidence quality, A; Grade of recommendation, strong).50

    2. The preponderance of evidence does not support treating preterm infants who have respiratory failure with iNO for the purpose of preventing/ameliorating BPD, severe intraventricular hemorrhage, or other neonatal morbidities (Evidence quality, A; Grade of recommendation, strong).

    3. The incidence of cerebral palsy, neurodevelopmental impairment, or cognitive impairment in preterm infants treated with iNO is similar to that of control infants (Evidence quality, A).

    4. The results of 1 multicenter, randomized controlled trial suggest that treatment with a high dose of iNO (20 ppm) beginning in the second postnatal week may provide a small reduction in the rate of BPD. However, these results need to be confirmed by other trials.

    5. An individual-patient data meta-analysis that included 96% of preterm infants enrolled in all published iNO trials found no statistically significant differences in iNO effect according to any of the patient-level characteristics, including gestational age, race, oxygenation index, postnatal age at enrollment, evidence of pulmonary hypertension, and mode of ventilation.

    6. There are limited data and inconsistent results regarding the effects of iNO treatment on pulmonary outcomes of preterm infants in early childhood.

    Lead Author

    Praveen Kumar, MD, FAAP

    Committee on Fetus and Newborn, 2012–2013

    Lu-Ann Papile, MD, FAAP, Chairperson

    Richard A. Polin, MD, FAAP

    Waldemar A. Carlo, MD, FAAP

    Rosemarie Tan, MD, FAAP

    Praveen Kumar, MD, FAAP

    William Benitz, MD, FAAP

    Eric Eichenwald, MD, FAAP

    James Cummings, MD, FAAP

    Jill Baley, MD, FAAP

    Liaisons

    Tonse N. K. Raju, MD, FAAP – National Institutes of Health

    CAPT Wanda Denise Barfield, MD, FAAP – Centers for Disease Control and Prevention

    Erin Keels, MSN – National Association of Neonatal Nurses

    Anne Jefferies, MD – Canadian Pediatric Society

    Kasper S. Wang, MD, FAAP – AAP Section on Surgery

    George Macones, MD – American College of Obstetricians and Gynecologists

    Staff

    Jim Couto, MA

    Footnotes

    • This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

    • The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

    • All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

    References

    1. ↵
      1. American Academy of Pediatrics, Committee on Fetus and Newborn
      . American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics. 2000;106(2 pt 1):344–345pmid:10920164
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Lin YJ,
      2. Markham NE,
      3. Balasubramaniam V,
      4. et al
      . Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res. 2005;58(1):22–29pmid:15879297
      OpenUrlCrossRefPubMedWeb of Science
      1. McCurnin DC,
      2. Pierce RA,
      3. Chang LY,
      4. et al
      . Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol. 2005;288(3):L450–L459pmid:15591412
      OpenUrlAbstract/FREE Full Text
      1. Ballard PL,
      2. Gonzales LW,
      3. Godinez RI,
      4. et al
      . Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res. 2006;59(1):157–162pmid:16326985
      OpenUrlCrossRefPubMedWeb of Science
      1. Bland RD,
      2. Albertine KH,
      3. Carlton DP,
      4. MacRitchie AJ
      . Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs. Am J Respir Crit Care Med. 2005;172(7):899–906pmid:15976381
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      1. Tang JR,
      2. Markham NE,
      3. Lin YJ,
      4. et al
      . Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L344–L351pmid:15064225
      OpenUrlAbstract/FREE Full Text
    4. ↵
      1. Clark RH,
      2. Ursprung RL,
      3. Walker MW,
      4. Ellsbury DL,
      5. Spitzer AR
      . The changing pattern of inhaled nitric oxide use in the neonatal intensive care unit. J Perinatol. 2010;30(12):800–804pmid:20237489
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      1. Cole FS,
      2. Alleyne C,
      3. Barks JD,
      4. et al
      . NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 2011;127(2):363–369pmid:21220405
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Askie LM,
      2. Ballard RA,
      3. Cutter GR,
      4. et al.,
      5. Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration
      . Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics. 2011;128(4):729–739pmid:21930540
      OpenUrlAbstract/FREE Full Text
    7. ↵
      1. Skimming JW,
      2. Bender KA,
      3. Hutchison AA,
      4. Drummond WH
      . Nitric oxide inhalation in infants with respiratory distress syndrome. J Pediatr. 1997;130(2):225–230pmid:9042124
      OpenUrlCrossRefPubMedWeb of Science
      1. Subhedar NV,
      2. Ryan SW,
      3. Shaw NJ
      . Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;77(3):F185–F190pmid:9462187
      OpenUrlAbstract/FREE Full Text
      1. Kinsella JP,
      2. Walsh WF,
      3. Bose CL,
      4. et al
      . Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999;354(9184):1061–1065pmid:10509496
      OpenUrlCrossRefPubMedWeb of Science
      1. The Franco-Belgium Collaborative NO Trial Group
      . Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet. 1999;354(9184):1066–1071pmid:10509497
      OpenUrlCrossRefPubMedWeb of Science
      1. Truffert P,
      2. Llado-Paris J,
      3. Mercier JC,
      4. Dehan M,
      5. Bréart G,
      6. Franco-Belgian iNO Study Group
      . Early inhaled nitric oxide in moderately hypoxemic preterm and term newborns with RDS: the RDS subgroup analysis of the Franco-Belgian iNO Randomized Trial. Eur J Pediatr. 2003;162(9):646–647pmid:12844257
      OpenUrlCrossRefPubMed
    8. ↵
      1. Srisuparp P,
      2. Heitschmidt M,
      3. Schreiber MD
      . Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome. J Med Assoc Thai. 2002;85(suppl 2):S469–S478pmid:12403222
      OpenUrlPubMed
    9. ↵
      1. Schreiber MD,
      2. Gin-Mestan K,
      3. Marks JD,
      4. Huo D,
      5. Lee G,
      6. Srisuparp P
      . Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349(22):2099–2107pmid:14645637
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      1. Van Meurs KP,
      2. Wright LL,
      3. Ehrenkranz RA,
      4. et al.,
      5. Preemie Inhaled Nitric Oxide Study
      . Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353(1):13–22pmid:16000352
      OpenUrlCrossRefPubMedWeb of Science
      1. Hascoet JM,
      2. Fresson J,
      3. Claris O,
      4. et al
      . The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr. 2005;146(3):318–323pmid:15756211
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      1. Field D,
      2. Elbourne D,
      3. Truesdale A,
      4. et al.,
      5. INNOVO Trial Collaborating Group
      . Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics. 2005;115(4):926–936pmid:15805366
      OpenUrlAbstract/FREE Full Text
    12. ↵
      1. Kinsella JP,
      2. Cutter GR,
      3. Walsh WF,
      4. et al
      . Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006;355(4):354–364pmid:16870914
      OpenUrlCrossRefPubMedWeb of Science
      1. Dani C,
      2. Bertini G,
      3. Pezzati M,
      4. Filippi L,
      5. Cecchi A,
      6. Rubaltelli FF
      . Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. Acta Paediatr. 2006;95(9):1116–1123pmid:16938760
      OpenUrlCrossRefPubMedWeb of Science
      1. Su PH,
      2. Chen JY
      . Inhaled nitric oxide in the management of preterm infants with severe respiratory failure. J Perinatol. 2008;28(2):112–116pmid:17989696
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Van Meurs KP,
      2. Hintz SR,
      3. Ehrenkranz RA,
      4. et al
      . Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. J Perinatol. 2007;27(6):347–352pmid:17443204
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      1. Ballard RA,
      2. Truog WE,
      3. Cnaan A,
      4. et al.,
      5. NO CLD Study Group
      . Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343–353pmid:16870913
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      1. Mercier JC,
      2. Hummler H,
      3. Durrmeyer X,
      4. et al.,
      5. EUNO Study Group
      . Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376(9738):346–354pmid:20655106
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      1. Jobe AH,
      2. Bancalari E
      . Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–1729pmid:11401896
      OpenUrlCrossRefPubMed
    17. ↵
      1. Stenmark KR,
      2. Abman SH
      . Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67:623–661pmid:15709973
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      1. Balasubramaniam V,
      2. Maxey AM,
      3. Morgan DB,
      4. Markham NE,
      5. Abman SH
      . Inhaled NO restores lung structure in eNOS-deficient mice recovering from neonatal hypoxia. Am J Physiol Lung Cell Mol Physiol. 2006;291(1):L119–L127pmid:16443642
      OpenUrlAbstract/FREE Full Text
      1. Tang JR,
      2. Seedorf G,
      3. Balasubramaniam V,
      4. Maxey A,
      5. Markham N,
      6. Abman SH
      . Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. Am J Physiol Lung Cell Mol Physiol. 2007;293(5):L1271–L1280pmid:17827251
      OpenUrlAbstract/FREE Full Text
    19. ↵
      1. Gutierrez HH,
      2. Nieves B,
      3. Chumley P,
      4. Rivera A,
      5. Freeman BA
      . Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. Free Radic Biol Med. 1996;21(1):43–52pmid:8791092
      OpenUrlCrossRefPubMedWeb of Science
    20. ↵
      1. Zhang YT,
      2. Zhang DL,
      3. Cao YL,
      4. Zhao BL
      . Developmental expression and activity variation of nitric oxide synthase in the brain of golden hamster. Brain Res Bull. 2002;58(4):385–389pmid:12183015
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      1. Soygüder Z,
      2. Karadağ H,
      3. Nazli M
      . Neuronal nitric oxide synthase immunoreactivity in ependymal cells during early postnatal development. J Chem Neuroanat. 2004;27(1):3–6pmid:15036358
      OpenUrlCrossRefPubMedWeb of Science
    22. ↵
      1. Cannon RO III,
      2. Schechter AN,
      3. Panza JA,
      4. et al
      . Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest. 2001;108(2):279–287pmid:11457881
      OpenUrlCrossRefPubMedWeb of Science
    23. ↵
      1. McMahon TJ,
      2. Moon RE,
      3. Luschinger BP,
      4. et al
      . Nitric oxide in the human respiratory cycle. Nat Med. 2002;8(7):711–717pmid:12042776
      OpenUrlPubMedWeb of Science
    24. ↵
      1. Bennett AJ,
      2. Shaw NJ,
      3. Gregg JE,
      4. Subhedar NV
      . Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. Acta Paediatr. 2001;90(5):573–576pmid:11430720
      OpenUrlPubMedWeb of Science
    25. ↵
      1. Mestan KK,
      2. Marks JD,
      3. Hecox K,
      4. Huo D,
      5. Schreiber MD
      . Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med. 2005;353(1):23–32pmid:16000353
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      1. Huddy CL,
      2. Bennett CC,
      3. Hardy P,
      4. et al.,
      5. INNOVO Trial Collaborating Group
      . The INNOVO multicentre randomised controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4–5 years. Arch Dis Child Fetal Neonatal Ed. 2008;93(6):F430–F435pmid:18375612
      OpenUrlAbstract/FREE Full Text
      1. Hintz SR,
      2. Van Meurs KP,
      3. Perritt R,
      4. et al.,
      5. NICHD Neonatal Research Network
      . Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. J Pediatr. 2007;151(1):16–22, 22.e1–e3pmid:17586184
      OpenUrlCrossRefPubMedWeb of Science
    27. ↵
      1. Watson RS,
      2. Clermont G,
      3. Kinsella JP,
      4. et al.,
      5. Prolonged Outcomes After Nitric Oxide Investigators
      . Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year. Pediatrics. 2009;124(5):1333–1343pmid:19841128
      OpenUrlAbstract/FREE Full Text
    28. ↵
      1. Walsh MC,
      2. Hibbs AM,
      3. Martin CR,
      4. et al.,
      5. NO CLD Study Group
      . Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide. J Pediatr. 2010;156(4):556–561.e1pmid:20138299
      OpenUrlCrossRefPubMedWeb of Science
    29. ↵
      1. Hibbs AM,
      2. Walsh MC,
      3. Martin RJ,
      4. et al
      . One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. J Pediatr. 2008;153(4):525–529pmid:18534620
      OpenUrlCrossRefPubMedWeb of Science
    30. ↵
      1. Hoo AF,
      2. Beardsmore CS,
      3. Castle RA,
      4. et al.,
      5. INNOVO Trial Collaborating Group
      . Respiratory function during infancy in survivors of the INNOVO trial. Pediatr Pulmonol. 2009;44(2):155–161pmid:19148936
      OpenUrlCrossRefPubMed
    31. ↵
      1. Barrington KJ,
      2. Finer N
      . Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2010;(12):CD000509pmid:21154346
      OpenUrlPubMed
    32. ↵
      1. Donohue PK,
      2. Gilmore MM,
      3. Cristofalo E,
      4. et al
      . Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics. 2011;127(2). Available at: www.pediatrics.org/cgi/content/full/127/2/e414pmid:21220391
      OpenUrlAbstract/FREE Full Text
    33. ↵
      1. Zupancic JA,
      2. Hibbs AM,
      3. Palermo L,
      4. et al.,
      5. NO CLD Trial Group
      . Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation. Pediatrics. 2009;124(5):1325–1332pmid:19841125
      OpenUrlAbstract/FREE Full Text
    34. ↵
      1. Truog WE,
      2. Ballard PL,
      3. Norberg M,
      4. et al.,
      5. Nitric Oxide (to Prevent) Chronic Lung Disease Study Investigators
      . Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Pediatrics. 2007;119(4):670–678pmid:17403837
      OpenUrlAbstract/FREE Full Text
      1. Ballard PL,
      2. Merrill JD,
      3. Truog WE,
      4. et al
      . Surfactant function and composition in premature infants treated with inhaled nitric oxide. Pediatrics. 2007;120(2):346–353pmid:17671061
      OpenUrlAbstract/FREE Full Text
    35. ↵
      1. Ballard PL,
      2. Truog WE,
      3. Merrill JD,
      4. et al
      . Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants. Pediatrics. 2008;121(3):555–561pmid:18310205
      OpenUrlAbstract/FREE Full Text
    36. ↵
      1. Posencheg MA,
      2. Gow AJ,
      3. Truog WE,
      4. et al.,
      5. NO CLD Investigators
      . Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites. J Perinatol. 2010;30(4):275–280pmid:19812581
      OpenUrlCrossRefPubMedWeb of Science
    37. ↵
      1. American Academy of Pediatrics Steering Committee on Quality Improvement and Management
      . Classifying recommendations for clinical practice guidelines. Pediatrics. 2004;114(3):874–877pmid:15342869
      OpenUrlAbstract/FREE Full Text
    • Copyright © 2014 by the American Academy of Pediatrics
    View Abstract
    PreviousNext

     

    Advertising Disclaimer »

    View this article with LENS
    PreviousNext
    Email

    Thank you for your interest in spreading the word on Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Use of Inhaled Nitric Oxide in Preterm Infants
    (Your Name) has sent you a message from Pediatrics
    (Your Name) thought you would like to see the Pediatrics web site.

    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Use of Inhaled Nitric Oxide in Preterm Infants
    Praveen Kumar, COMMITTEE ON FETUS AND NEWBORN
    Pediatrics Jan 2014, 133 (1) 164-170; DOI: 10.1542/peds.2013-3444

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Use of Inhaled Nitric Oxide in Preterm Infants
    Praveen Kumar, COMMITTEE ON FETUS AND NEWBORN
    Pediatrics Jan 2014, 133 (1) 164-170; DOI: 10.1542/peds.2013-3444
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Print
    PDF
    Insight Alerts
    • Table of Contents
    • Current Policy
    • Early Release
    • Current Issue
    • Past Issues
    • Editorial Board
    • Editorial Policies
    • Overview
    • Features Video
    • Open Access
    • Pediatric Collections
    • Video Abstracts
    • Author Guidelines
    • Reviewer Guidelines
    • Submit My Manuscript

    Subjects

    • Fetus/Newborn Infant
      • Fetus/Newborn Infant
      • Neonatology
    • AAP Policy Collections by Authoring Entities
      • Committee on Fetus & Newborn
    • Pharmacology
      • Toxicology
      • Pharmacology
    Back to top

                

    Copyright © 2019 by American Academy of Pediatrics

    International Access »

    Terms of Use
    The American Academy of Pediatrics (AAP) takes the issue of privacy very seriously. See our Privacy Statement for information about how AAP collects, uses, safeguards and discloses the information collected on our Website from visitors and by means of technology.
    FAQ

     

    AAP Pediatrics